US federal judge ruling means Talor Gooch, Hudson Swafford and Matt Jones cannot take part in FedEx Cup Playoffs.
Macau has seen its casino industry sales shrink by a whopping 95 percent following China’s rigorous zero-COVID-19 policy, setting an all-time low record ever since statistics were made available in 2009.
The number 45 is embroidered on the lace to signify the 45th anniversary of the McDonald's All-American game, despite the fact that this is not an official McDonald's cooperation.
The complaint charged Musk with breaking a long list of merger agreement provisions that "have soured Twitter and its operations."
New Balance will soon release a number of inline colorways of 1906, the first of which is scheduled to hit China on August 19th and August 12th in the rest of Asia.
LaLiga Tech has aided sports properties to safeguard over $9.2 billion in content and build more beneficial and direct links with their fans, demonstrating technology's potential to improve the business.
Mykeyring products were created in accordance with official license agreements with license holders.
America’s Roundup: Dollar edges higher as traders await U.S. inflation report, Wall ends lower, Gold ticks up, Oil settles lower as halted Russian pipeline flows appear temporary, demand fears rise-August 10th,2022
SEC's climate disclosure plan could be in trouble after a recent Supreme Court ruling, but a bigger question looms: Does disclosure work?
Johnson & Johnson spends $800 million to settle most gynecomastia lawsuits
Johnson & Johnson disclosed that it spent $800 million in settling "substantially all" of the roughly 9,000 cases by men who claimed having developed excessive breast tissue in using the company's antipsychotic drug Risperdal.
The company said it reached the agreement with lawyers handling the cases, including a lawsuit in Philadelphia by Maryland resident Nicholas Murray, who was awarded an $8 billion in punitive damage by a jury award in 2019. A judge has since reduced the award to $6.8 million.
The lawsuits, filed in Pennsylvania, California, and Missouri, generally accused J&J of failing to warn of the risk called gynecomastia associated with Risperdal, which they claimed were marketed for off-label, unapproved uses with children.
The company denied the allegations.
In 1993, the US Food and Drug Administration approved Risperdal for treating schizophrenia and bipolar mania in adults. It was only in 2006 that it was approved for treating irritability associated with autism in children.
The company separately agreed in 2013 to pay $2.2 billion to settle US criminal and civil probes into its marketing of Risperdal and two other drugs.
In May, the US Supreme Court rejected J&J's bid to overturn a $70 million jury verdict against it for its failure to warn about risks associated with using Risperdal.